Request Sample
Request Methodology
Description
The Global Biopsy Devices Market was valued at USD 1.64 billion in 2021 and is anticipated to grow at USD 2.43 billion till 2028 recording a CAGR of 6.9% during the forecast period 2022-2028. Biopsy is a surgical operation that involves removing tissue from an organ to detect the existence or degree of a disease, most commonly cancer and inflammatory disorders. Surgeons, radiologists, and interventional cardiologists are the most common practitioners. As a confirmatory test for cancer and celiac disease, biopsies can be conducted on any organ using specialised biopsy instruments. The type of organ under consideration determines how each biopsy equipment is used. Advanced imaging technologies, such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others, can be used in conjunction with traditional biopsy techniques to perform biopsy with accuracy and least invasiveness. Biopsies of body organs such as the lungs, liver, and kidneys are performed using these integrated methods. The biopsy is a minimally invasive surgical process performed to remove the tissue from the body for the determination of presence or extent of diseases such as cancer and inflammatory conditions. Generally, the biopsy is carried by radiologists, surgeons, and interventional cardiologists to confirm the presence of disease. A biopsy can be carried for the majority of organs in the body with the aid of specific biopsy devices. The various types of biopsy devices include skin biopsy, shave biopsy, fine needle aspiration, excision and incision biopsy, and vacuum-assisted biopsy among others. Conventional biopsy devices are complimented with the advanced imaging technologies like stereotactic-guided biopsy, CT scan, MRI-guided, ultrasound-guided biopsy, and others. These devices are helping to perform the biopsies in critical areas such as liver, kidney, and lungs. In August 2017, Hologic launched Bravera a breast biopsy system used for real-time breast biopsy and verification. In September 2016, SmartTarget Ltd launched its CE marked biopsy device used in the diagnosis of prostate cancer in U.K.
